Erste Group Bank Predicts Gilead Sciences FY2026 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Erste Group Bank raised their FY2026 EPS estimates for Gilead Sciences in a report released on Wednesday, October 21st. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings of ($0.41) per share for the year, up from their prior estimate of ($0.44). The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.48) per share.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period in the prior year, the company earned $2.01 EPS. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis.

Several other brokerages have also recently commented on GILD. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Morgan Stanley cut their price target on Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. HSBC lifted their price target on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Finally, Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $159.81.

Gilead Sciences Trading Up 1.7%

Shares of GILD opened at $158.69 on Monday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a fifty day moving average price of $148.84 and a two-hundred day moving average price of $138.77. Gilead Sciences has a 52-week low of $114.02 and a 52-week high of $160.51.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Gilead Sciences during the 2nd quarter valued at about $15,393,785,000. State Street Corp boosted its stake in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares during the last quarter. Amundi boosted its stake in shares of Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $1,316,606,000. Finally, Deutsche Bank AG acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $918,387,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock worth $15,877,860 over the last ninety days. 0.30% of the stock is currently owned by insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: An analyst raised the fiscal 2026 EPS forecast for Gilead, signaling improved expectations for the company’s earnings outlook. FY2026 EPS Forecast for Gilead Sciences Raised by Analyst
• Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide medicines. The transaction may support investor optimism about Gilead’s business-development strategy and longer-term growth opportunities in this emerging market. Gilead’s Latest Deal Shows Big Pharma’s Appetite for Oral Peptides
• Neutral Sentiment: Investors are preparing for Gilead’s third-quarter 2026 earnings report. Analysts are focused not only on revenue and EPS but also on operating metrics that could provide clues about product performance and the company’s outlook. Ahead of Gilead Q3 Earnings
• Neutral Sentiment: Recent coverage compares Gilead with Amgen as a dividend investment. Gilead offers a forward dividend yield above 2% and a lower payout ratio, although Amgen is reported to have stronger sales growth. Amgen vs. Gilead Sciences
• Negative Sentiment: The reported October short-interest data lists short interest at zero shares and a zero-day short-interest ratio despite describing a large increase. This apparent inconsistency limits its usefulness as a reliable signal of bearish positioning.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.